Intellia Therapeutics, Inc. (NASDAQ:NTLA) Receives Average Recommendation of “Moderate Buy” from Brokerages

Shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA) have received an average rating of “Moderate Buy” from the twenty-one ratings firms that are covering the stock, MarketBeat.com reports. Two equities research analysts have rated the stock with a sell rating, six have assigned a hold rating and thirteen have issued a buy rating on the company. The average 1-year target price among analysts that have issued a report on the stock in the last year is $27.95.

Several equities research analysts have commented on NTLA shares. Wedbush reaffirmed a “neutral” rating and set a $7.00 price objective on shares of Intellia Therapeutics in a report on Monday, June 16th. Wall Street Zen upgraded Intellia Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, September 6th. Citizens Jmp upgraded Intellia Therapeutics from a “market perform” rating to an “outperform” rating and set a $33.00 price target on the stock in a research report on Monday. Chardan Capital decreased their price target on Intellia Therapeutics from $68.00 to $60.00 and set a “buy” rating on the stock in a research report on Monday, August 11th. Finally, JMP Securities upgraded Intellia Therapeutics from a “market perform” rating to a “market outperform” rating and set a $33.00 price target on the stock in a research report on Monday.

Intellia Therapeutics Stock Up 2.9%

NASDAQ NTLA opened at $20.54 on Tuesday. The company has a market cap of $2.20 billion, a PE ratio of -4.38 and a beta of 2.37. Intellia Therapeutics has a 52 week low of $5.90 and a 52 week high of $21.49. The firm’s 50-day simple moving average is $13.03 and its two-hundred day simple moving average is $10.41.

Intellia Therapeutics (NASDAQ:NTLA) last released its quarterly earnings data on Thursday, August 7th. The company reported ($0.99) EPS for the quarter, beating the consensus estimate of ($1.03) by $0.04. The business had revenue of $14.25 million for the quarter, compared to the consensus estimate of $12.26 million. Intellia Therapeutics had a negative net margin of 908.48% and a negative return on equity of 57.48%. The company’s revenue was up 104.3% compared to the same quarter last year. During the same period in the prior year, the firm earned ($1.52) earnings per share. As a group, equities research analysts anticipate that Intellia Therapeutics will post -5.07 EPS for the current year.

Insider Activity

In other news, EVP Edward J. Dulac III sold 7,462 shares of the company’s stock in a transaction dated Wednesday, July 23rd. The stock was sold at an average price of $14.02, for a total transaction of $104,617.24. Following the sale, the executive vice president directly owned 106,062 shares in the company, valued at $1,486,989.24. This represents a 6.57% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this link. Also, CAO Michael P. Dube sold 1,871 shares of the company’s stock in a transaction dated Wednesday, October 1st. The shares were sold at an average price of $17.38, for a total value of $32,517.98. Following the sale, the chief accounting officer owned 55,266 shares in the company, valued at approximately $960,523.08. This represents a 3.27% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 9,364 shares of company stock worth $137,674 over the last ninety days. Company insiders own 3.10% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the stock. Benjamin Edwards Inc. increased its position in shares of Intellia Therapeutics by 1.8% in the second quarter. Benjamin Edwards Inc. now owns 63,034 shares of the company’s stock worth $591,000 after purchasing an additional 1,126 shares during the last quarter. HighTower Advisors LLC increased its position in shares of Intellia Therapeutics by 8.2% in the first quarter. HighTower Advisors LLC now owns 16,921 shares of the company’s stock worth $120,000 after purchasing an additional 1,282 shares during the last quarter. Johnson Financial Group Inc. increased its position in shares of Intellia Therapeutics by 24.8% in the second quarter. Johnson Financial Group Inc. now owns 6,988 shares of the company’s stock worth $66,000 after purchasing an additional 1,388 shares during the last quarter. Harbour Investments Inc. increased its position in shares of Intellia Therapeutics by 27.2% in the second quarter. Harbour Investments Inc. now owns 6,633 shares of the company’s stock worth $62,000 after purchasing an additional 1,419 shares during the last quarter. Finally, Ameriprise Financial Inc. increased its position in shares of Intellia Therapeutics by 13.9% in the second quarter. Ameriprise Financial Inc. now owns 11,803 shares of the company’s stock worth $111,000 after purchasing an additional 1,443 shares during the last quarter. 88.77% of the stock is currently owned by institutional investors.

About Intellia Therapeutics

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.